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in the Colyte-Dulcolax group and 341 in the Phospho-soda group). The demographics of the patients were not reported. Phase I reflected current practice, but there was a prescribing preference for Colyte-Dulcolax. Therefore, in Phase II preference was given to Phospho-soda, unless there was a specific contraindication. Phase III was a confirmatory period that was carried out to determine patient preferences for the two medications.
Study design
This was a prospective cohort study that was carried out in a single centre, the Gastroenterology Clinic at the US National Naval Medical Center, Bethesda (MD). No follow-up was performed and there was no explicit blinding of the outcome assessment.
Analysis of effectiveness
All of the patients included in the initial study sample were accounted for in the analysis of effectiveness. The outcome measures used were:
clinical effectiveness, based on the evaluations of 12 examining endoscopists who ranked the effectiveness of the study medication on colon preparation using seven criteria ranging from "excellent" to "poor"; patient tolerability (i.e. incidence of nausea and/or vomiting); patient compliance (i.e. amount of medication consumed by the patients); and patient preference toward the study medication, which was assessed in a sub-group of 71 respondents of 84 patients in the Phospho-soda group who had previously received Colyte-Dulcolax.
The outcomes were assessed using a questionnaire. The baseline comparability of the study groups was not discussed.
Effectiveness results
The participating endoscopists rated colon preparation as excellent-to-good in 88% of the Phospho-soda group and in 76% of the Colyte-Dulcolax group, (p<0.01). The rate of adequate-to-fair assessment was 10% (Phospho-soda) versus 21% (Colyte-Dulcolax). The rate of poor assessment was 2% (Phospho-soda) versus 3% (Colyte-Dulcolax).
There was no statistically significant difference in patient tolerability. Nausea and/or vomiting were reported in 5% of Phospho-soda patients and in 7% of Colyte-Dulcolax patients. Nausea without vomiting was observed in 18% of Phospho-soda patients and in 21% of Colyte-Dulcolax patients.
Significantly more Phosphate-soda patients than Colyte-Dulcolax patients were able to drink all of the preparation. The difference was statistically significant.
Of the 71 patients who had received both medications (Phospho-soda in the current evaluation and Colyte-Dulcolax for previous colonoscopies), 68 patients (96%) preferred Phospho-soda.
Clinical conclusions
The effectiveness analysis showed that Phospho-soda was well tolerated and was more effective than Colyte-Dulcolax. Patients preferred Phospho-soda to Colyte-Dulcolax and the compliance rate was higher.
Measure of benefits used in the economic analysis
The health outcomes were left disaggregated and no summary benefit measure was used in the economic analysis. In effect, a cost-consequences analysis was performed.
